Afimoxifene, also known as 4-hydroxytamoxifen, is a selective estrogen receptor modulator (SERM) that is recognized as the active metabolite of the well-known drug, tamoxifen. Unlike tamoxifen, which is typically administered orally, afimoxifene is formulated as a transdermal gel.
Ascend Therapeutics, Inc. is the company behind the development of afimoxifene, marketing it under the trademark name TamoGel. This transdermal gel formulation provides a unique method of delivery, which may offer advantages over traditional oral administration.
Afimoxifene has undergone several clinical trials to evaluate its efficacy and safety:
Phase II Clinical Trial: A significant phase II clinical trial was conducted focusing on the potential use of afimoxifene for the treatment of cyclical mastalgia, a condition characterized by breast pain related to menstrual cycles.
Comparative Study with Tamoxifen: A noteworthy study carried out in France included 55 women and indicated that the topical application of afimoxifene directly to the skin was as effective as orally-administered tamoxifen tablets in decelerating the growth of breast cancer. The advantages of such topical application include a significant reduction in systemic levels (by a factor of nine), which can potentially minimize the undesired side effects commonly associated with tamoxifen. A subsequent trial in the US is set to compare the outcomes of 6 weeks of afimoxifene use prior to undergoing breast cancer surgery.
One of the primary anticipated benefits of afimoxifene's topical application is a marked decrease in the systemic exposure to the drug. This could lead to a significant reduction in the side effects generally seen with tamoxifen, making the treatment more tolerable for patients.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer. Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
